ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Refludan®:Celgene International Sàrl
Complete information for professionalsDDDPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
Registration ownerLast update of information 
B01AE02 - LepirudinATC-DDD Version 2016. Source: WHO
B - Blood and Blood Forming Organs
 
B01 - Antithrombotic Agents
 
B01A - Antithrombotic Agents
 
B01AE - Direct Thrombin Inhibitors
 

The DDD for dabigatran etexilate is based on treatment of patients with NVAF (nonvalvular atrial fibrillation).

B01AE02 - Lepirudin
DoseRoute of administrationNote
 P 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home